COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT CONTAINING CRIZOTINIB FOR NON SMALL CELL LUNG CANCER (ALK plus ) PATIENTS

被引：0
|
作者：
Sabater Cabrera, E. [1 ]
Puente, J. [2 ]
Oyaguez, I [3 ]
Garcia-Campelo, R. [4 ]
Reguart, N. [5 ]
Rodriguez, D. [6 ]
Cobo, M. [7 ]
Soto, J. [8 ]
Moran, M. [8 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Pharmacoecon & Outcomes Res Iberia, Pozuelo De Alarcon, Spain
[4] Hosp Univ A Coruna, La Coruna, Spain
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] Compiejo Hosp Univ Insular Materno Infantil, Las Palmas Gran Canaria, Spain
[7] Hosp Reg Malaga Carlos Haya, Malaga, Spain
[8] Pfizer Spain, Alcobendas, Spain
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.259
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN176
引用
收藏
页码：A443 / A444
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
  • [2] Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK plus advanced non-small-cell lung cancer in France
    Sivignon, Marine
    Monnier, Remi
    Tehard, Bertrand
    Roze, Stephane
    [J]. PLOS ONE, 2020, 15 (01):
  • [3] Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer in Canada
    Hurry, Manjusha
    Zhou, Zheng-Yi
    Zhang, Jie
    Zhang, Chenxue
    Fan, Liangyi
    Rebeira, Mayvis
    Xie, Jipan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 936 - 944
  • [4] Treatment After Crizotinib Resistance in ALK plus Non-Small-Cell Lung Cancer
    Kazaz, Seher N.
    Oztop, Ilhan
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2017, 27 (01): : 60 - 68
  • [5] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY TREATED PATIENTS WITH CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN CANADA
    Zhou, Z.
    Hurry, M.
    Zhang, J.
    Fan, L.
    Zhang, C.
    Xie, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A462 - A462
  • [6] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    [J]. PLOS ONE, 2018, 13 (10):
  • [7] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [8] COST-EFFECTIVENESS OF EML4-ALK FUSION TESTING IN COMBINATION WITH CRIZOTINIB TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER LIVING IN ONTARIO
    Djalalov, S.
    Hoch, J. S.
    Beca, J.
    Krahn, M.
    Tsao, M. S.
    Cutz, J. C.
    Leighl, N.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A142 - A142
  • [9] BUDGET IMPACT ANALYSIS OF CRIZOTINIB TREATMENT IN ALK plus NON-SMALL CELL LUNG CANCER PATIENTS IN THAILAND
    Permsuwan, U.
    Petcharapiruch, S.
    Thongprasert, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A719 - A719
  • [10] COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN UNITED STATES
    Zhang, Y.
    Shao, Y.
    Shi, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S32 - S32
12345